Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Il-Yang Pharm. Co., Ltd.
ClinicalTrials.gov Identifier:
NCT01602952
First received: April 20, 2012
Last updated: March 4, 2014
Last verified: March 2014

April 20, 2012
March 4, 2014
July 2008
October 2012   (final data collection date for primary outcome measure)
  • To investigate the Maximum Tolerated Dose(Phase 1) [ Time Frame: 12 month ] [ Designated as safety issue: No ]
    Radotinib will be given orally twice daily. Dose will be increased until it reaches MTD or the blood concentration of Radotinib stops rising
  • Rate of Complete hematologic response(CHR)(Phase 2) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Main parameters for response assessment in the chronic and accelerated phases include Major Hematologic Responses (MR; No Evidence of Leukemia or NEL + Complete Hematologic Response or CHR) lasting for 4 weeks and at least one major cytogenetic response (MCyR)
Same as current
Complete list of historical versions of study NCT01602952 on ClinicalTrials.gov Archive Site
  • To investigate the Dose Limiting Toxicity(Phase 1) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    The initial cohort will include 3 subjects who will receive 100mg Radotinib daily. If DLT is observed in one of the 3 subjects, the same dose will be given to 3 more subjects to evaluate safety.
  • Rate of complete Cytogenetic Response(CCyR)(Phase 2) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    Cytogenetic response rate will be calculated as the percentage of Ph+ bone marrow metaphases as follows at least 20 bone marrow metaphases should be analyzed.
  • Adverse events(Phase 1& Phase 2) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    All adverse events recorded during the study will be itemized and summarized. Severity, relation to the study medication, and seriousness will be summarized for each adverse event.
  • Progression-free survival or PFS [ Time Frame: 12 months ] [ Designated as safety issue: No ]
    It is defined as the duration from the first day of administration to the earliest day of disease progression or death for certain causes. In subjects who have shown response, disease progression is defined as loss of MCyR.
Same as current
Not Provided
Not Provided
 
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
A Phase I/II Multicenter Study of IY5511HCl in Philadelphia Chromosome Positive Chronic Myeloid Leukemia Patients Without Optimal Response or Tolerance to Bcr-Abl Tyrosine Kinase Inhibitors (Imatinib and/ or Dasatinib, Nilotinib)

A Phase I/II multicenter study of IY5511HCl in Philadelphia chromosome positive chronic myeloid leukemia patients without optimal response or tolerance to Bcr-Abl tyrosine kinase inhibitors (Imatinib and/ or Dasatinib, Nilotinib) In this study, The efficacy and safety of CML patients who are resistant or intolerable to imatinib in the Chronic and Accelerated phases.

Phase 1

1. To investigate the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicity (DLT) of oral Radotinib HCl bid (twice daily) in the Philadelphia chromosome-positive CML subjects who are resistant, suboptimal responsive, or intolerant to imatinib OR resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously.

Phase 2

  1. To investigate safety of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.
  2. To evaluate hematologic and cytogenetic efficacy of oral Radotinib HCl in CML patients who are resistant or intolerable to imatinib in the chronic and accelerated phases.

This study is a multi-center, open-label, Phase 1/2 clinical trial of Radotinib HCl, a targeted anticancer agent that inhibits the Bcr-Abl oncoprotein. It is aimed at determining the optimal therapeutic dose and confirming safety and efficacy of Radotinib HCl. Phase 1 study began at St. Mary's hospital in Korea and Phase 2 study is ongoing at 9 Korean sites and about 7 sites in China, India and Thailand will take part in Phase 2. After determination of a safe and proper therapeutic dose in Phase 1, Phase 2 began continuously to evaluate efficacy in chronic and accelerated phases. Before the start of the Phase 2 trial, interim or final reports for the Phase 1 trial were reviewed by the Korean Food and Drug Administration.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Philadelphia Chromosome
  • Hematologic Diseases
Drug: Radotinib
50mg, 100mg or 200mg Capsule BID
Other Name: IY5511HCl
Experimental: Radotinib

Phase 1 : 200mg/kg or 1200mg/m^2

Phase 2 : 400mg Bid

Intervention: Drug: Radotinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
85
December 2015
October 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Phase I

  1. Age ≥ 18 years old
  2. Ph+ CML patients who are resistant at chronic, accelerate, and acute phase, or suboptimal responsive, or intolerant to imatinib or resistant or intolerant to at least one second-generation targeted anticancer agent while being resistant, suboptimal responsive, or intolerant to imatinib simultaneously.
  3. WHO Performance status of ≤2
  4. Patients must have the following laboratory values With normal liver and renal function
  5. Patients who have received interferon, other anti cancer drug or radiotherapy > 1 week prior to starting study drug.

Phase II

  1. Age ≥ 18 years old
  2. Ph+ CML patients in chronic or accelerated phase who are resistant or intolerant to Imatinib mesylate
  3. WHO Performance status of ≤2
  4. Patients must have the following laboratory values With normal liver and renal function
  5. Patients who have received interferon, other anti cancer drug or radiotherapy > 1 week prior to starting study drug.

Exclusion Criteria:

Phase I

  1. CNS infiltration
  2. Impaired cardiac function, including any one of the followings.

    • LVEF <45% as determined by MUGA scan or echocardiogram
    • Clinically significant resting bradycardia
  3. Severe GI disease that may cause drug absorption problem of study drug
  4. Use of therapeutic Warfarin
  5. Acute or chronic liver or renal disease
  6. Other concurrent severe and/or uncontrolled medical conditions
  7. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to starting study drug.
  8. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval
  9. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy ≤ 1 week
  10. Patients who have received Nilotinib and Dasatinib ≤4 weeks prior to starting study drug.
  11. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  12. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control.
  13. Patients not to agree using birth control during the study and for up 3 months following study completion.

15. HIV infection

Phase II

  1. Blast phase CML
  2. CNS infiltration
  3. Impaired cardiac function, including any one of the following

    • LVEF< 45% as determined by MUGA scan or echocardiogram
    • Use of Cardiac pacemaker
    • ST depression > 1mm in 2 or more leads and/or T wave inversions in 2 or more contiguous leads
    • Congenital long QT syndrome
    • History of, or presence of significant ventricular or atrial tachyarrhythmias
    • Clinically significant resting bradycardia
    • QTcF> 480 msec on screening ECG
    • Right bundle branch block + left anterior hemiblock, Bifascicular block
    • Angina pectoris
  4. Severe GI disease that may cause drug absorption problem of study
  5. Use of therapeutic Warfarin
  6. Acute or chronic liver or renal disease
  7. Other concurrent severe and/or uncontrolled medical conditions
  8. Treatment with any hematopoietic colony-stimulating growth factors ≤1 week prior to starting study drug.
  9. Patients who are currently receiving treatment with medications have the potential to prolong the QT interval
  10. Patients who have received Imatinib, interferon, other anti cancer drug or chemotherapy ≤ 1 week
  11. Patients who have received wide field radiotherapy ≤4 weeks prior to starting study drug.
  12. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  13. Patients who are pregnant or breast-feeding or adults of reproductive potential not employing an effective method of birth control
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
India,   Korea, Republic of,   Thailand
 
NCT01602952
IY5511A1201
No
Il-Yang Pharm. Co., Ltd.
Il-Yang Pharm. Co., Ltd.
Not Provided
Study Director: IL-yang Pharm IL-YANG Pharmaceutical.Co.,Ltd.
Il-Yang Pharm. Co., Ltd.
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP